NCT06908304 2026-01-12
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
Maia Biotechnology
Phase 3 Recruiting
Maia Biotechnology
Seagen Inc.
Tianjin Medical University Cancer Institute and Hospital
SWOG Cancer Research Network
Eli Lilly and Company